Wednesday, October 7, 2026

How We Source Explore Search

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· July 4, 2026

Crypto News: Pepeto Presale Passes $10.38 Million While Bitcoin Price Prediction Drops to $82,000 and Ethereum Jumps on Warsh Signal

View original at globenewswire.com

Crypto News: Pepeto Presale Passes $10.38 Million While Bitcoin Price Prediction Drops to $82,000 and Ethereum Jumps on Warsh Signal DUBAI, United Arab Emirates, July 04, 2026 (GLOBE NEWSWIRE) -- Ethereum Based crypto Pepeto keeps advancing fast week after week, with funds now exceeding $10.38, the only presale in 2026…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Bitcoin will reach $150,000 by December 2026
60% confidence
Unverified rumor connecting Donald Trump to Pepeto
60% confidence
Presale listings have historically returned 30x or more on day one
60% confidence
Inflation risks have eased
60% confidence
Long-term Bitcoin holders are accumulating again
60% confidence
Speculation that Elon Musk is involved behind the scenes with Pepeto
60% confidence

Data points we hold from this source

Pepeto · presale funds raised	10.38 USD
Bitcoin · analyst price target	150000 USD

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs

Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,362 source documents archived

Query this data → isubstrate.com